Hydroxyurea to prevent brain injury in children with sickle cell disease (HU Prevent)—A randomized, placebo‐controlled phase II feasibility/pilot study is a research paper published in American Journal of Hematology (2024). On theSindex it has a DataRank of 0. It has been cited 12 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Heart, Lung, and Blood Institute
Grant: R34 HL108756
National Heart, Lung, and Blood Institute
Grant: U34 HL148480
National Center for Advancing Translational Sciences
Grant: U24TR001609
National Center for Advancing Translational Sciences
Grant: U24TR004440
National Center for Advancing Translational Sciences
Grant: UL1 TR003098
NCATS NIH HHS
Grant: UL1 TR002345
NICHD NIH HHS
Grant: P50 HD103537
NCRR NIH HHS
Grant: UL1 RR024992
FWCI
3.46
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals